retatrutide trial weight loss The numbers from Lilly's Phase 3 dropped this week and I haven't been able to stop thinking about them. Not only as a doctor but as a long-term GLP-1 user Retatrutide: A Promising Option for

All trials revealed cardiovascular safety by establishing non-inferiority

If you already struggle with delayed emptying, adding a drug that intensifies this is likely to worsen symptoms

Zhuge F, Ni Y, Nagashimada M, Nagata N, Xu L, Mukaida N, et al

Many healthcare providers may not yet be aware of this association because allodynia is not listed on the semaglutide drug label and the research is recent

Achieves significant weight reduction through simultaneous GIP, GLP-1, and glucagon receptor activation in preclinical models

Injectable GLP-1 medications are peptide-based drugs administered via subcutaneous injection, bypassing the gastrointestinal tract for absorption